Physician profile
Adam J Kreitenberg
NPI 1770857682
$862,684.32
in general payments reported to CMS, 2019-2025
48 companies · $197K in 2025
The $197K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $40K · 2021: $68K · 2022: $130K · 2023: $206K · 2024: $177K · 2025: $197K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $466K · Travel and Lodging: $67K · Food and Beverage: $27K · Consulting Fee: $18K · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $466,035.00 |
| Travel and Lodging | $67,447.22 |
| Food and Beverage | $27,231.92 |
| Consulting Fee | $18,403.00 |
| Education | $176.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $279,235.64 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $183,753.04 | 2019-2024 | Taltz |
| Astrazeneca Pharmaceuticals Lp | $114,596.71 | 2021-2025 | Saphnelo |
| Abbvie INC. | $105,090.26 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $57,526.14 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $53,793.36 | 2019-2025 | |
| Glaxosmithkline, LLC. | $52,888.00 | 2019-2025 | Benlysta |
| Amgen INC. | $5,043.30 | 2019-2025 | Enbrel, Otezla, Evenity |
| Ucb, INC. | $1,726.02 | 2019-2025 | Cimzia, Bimzelx |
| Alexion Pharmaceuticals, INC. | $1,385.44 | 2019-2025 | Strensiq |
| Radius Health, INC. | $974.22 | 2019-2025 | Tymlos |
| Pfizer INC. | $748.65 | 2019-2025 | |
| Horizon Therapeutics Plc | $626.94 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $527.80 | 2020-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $494.83 | 2019-2025 | Orencia, Sotyktu |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $494.44 | 2021-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.05 | 2022-2025 | Ofev, Cyltezo |
| Fresenius Kabi USA, LLC | $316.71 | 2023-2025 | Idacio, Adalimumab-Aacf |
| Celgene Corporation | $313.63 | 2019 | |
| Ani Pharmaceuticals, INC. | $294.90 | 2022-2025 | Purified Cortrophin Gel |
| Hikma Pharmaceuticals USA | $272.27 | 2019-2022 | |
| Octapharma USA, INC. | $270.18 | 2021-2025 | Octagam Immune Globulin (Human), Panzyga |
| Genzyme Corporation | $269.32 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $239.87 | 2019 | |
| Organon LLC | $179.03 | 2023-2025 | Hadlima, Renflexis |
| Dr.Reddy'S Laboratories,INC. | $163.00 | 2025 | Methylprednisolone Sodium Succinate |
| Kiniksa Pharmaceuticals International, Plc | $150.72 | 2024 | Arcalyst |
| Sobi, INC | $120.56 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $81.20 | 2023 | |
| Depuy Synthes Sales INC. | $71.12 | 2021-2024 | Orthovisc, Monovisc |
| Merck Sharp & Dohme LLC | $70.38 | 2019-2020 | |
| Bioventus LLC | $51.92 | 2019-2022 | |
| Invivyd INC | $51.82 | 2025 | Pemgarda |
| Gilead Sciences, INC. | $51.52 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $50.49 | 2024 | Truxima, Simlandi |
| Alvogen INC | $46.21 | 2025 | Teriparatide |
| Kyowa Kirin, INC. | $45.94 | 2023 | Crysvita |
| Fidia Pharma USA INC. | $42.96 | 2020-2024 | Hyalgan, Hymovis, Triluron |
| Vertiflex, INC. | $41.78 | 2019 | |
| Angiodynamics, INC. | $41.42 | 2021 | |
| Celltrion USA INC. | $37.16 | 2025 | Vegzelma |
| Ultragenyx Pharmaceutical INC. | $36.12 | 2019-2021 | |
| Medexus Pharma, INC. | $34.85 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $31.11 | 2024 | Zilretta |
| Genentech USA, INC. | $27.28 | 2024 | Actemra |
| Novo Nordisk INC | $26.23 | 2025 | Saxenda, Wegovy |
| Zimmer Biomet Holdings, INC. | $15.56 | 2025 | Gel-One Cross-Linked Hyaluronate |
| Tactile Systems Technology INC | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Kreitenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.